HomeInsightsPE

Jubilant Pharmova Ltd PE Ratio

Jubilant Pharmova Ltd PE Ratio

stocks purchased

₹ 0.9 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

7.9 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 22, 2024

Image

Jubilant Pharmova Ltd

NSE: JUBLPHARMA

PE

63

Last updated on: Nov 22, 2024

Key Highlights

  • The P/E Ratio of Jubilant Pharmova Ltd is 63 as of 22 Nov 15:30 PM .
  • The P/E Ratio of Jubilant Pharmova Ltd changed from 18.4 on March 2019 to 116.5 on March 2024 . This represents a CAGR of 36.01% over 6 years.
  • The Latest Trading Price of Jubilant Pharmova Ltd is ₹ 1141 as of 22 Nov 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Jubilant Pharmova Ltd

No data available

Company Fundamentals for Jubilant Pharmova Ltd

No data available

Image

Jubilant Pharmova Ltd

NSE: JUBLPHARMA

Share Price

₹ 1141.2

10.35 (0.92%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Jubilant Pharmova Ltd

1M

1Y

3Y

5Y

Monitoring Jubilant Pharmova Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 20241141.2
21 Nov 20241130.85
19 Nov 20241131.1
18 Nov 20241145.1
14 Nov 20241166.9
13 Nov 20241145.45
12 Nov 20241189.65
11 Nov 20241225.45
08 Nov 20241236.95
07 Nov 20241256.35

SWOT Analysis Of Jubilant Pharmova Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Jubilant Pharmova Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Jubilant Pharmova Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Jubilant Pharmova Ltd6218,179
Sun Pharmaceuticals Industries Ltd384,31,352
Divis Laboratories Ltd861,59,265
Cipla Ltd261,20,033
Torrent Pharmaceuticals Ltd611,07,301
Mankind Pharma Ltd481,02,231

Key Valuation Metric of Jubilant Pharmova Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Jubilant Pharmova Ltd

No data available

* All values are in crore

Historical Revenue of Jubilant Pharmova Ltd

No data available

* All values are in crore

Historical EBITDA of Jubilant Pharmova Ltd

No data available

* All values are in crore

Historical Net Profit of Jubilant Pharmova Ltd

No data available

* All values are in crore

Historical Dividend Payout of Jubilant Pharmova Ltd

No data available

* All values are in %

About Jubilant Pharmova Ltd

  • Jubilant Pharmova Limited, (Formerly known as Jubilant Life Sciences Limited), is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
  • The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
  • The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions.

Jubilant Pharmova Ltd News Hub

News

Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories

Jubilant Biosys Innovative Research Services,, Singapore (JBIRSPL), subsidiary of Jubilant...

Read more

2024-08-16 00:00:00

News

Volumes soar at Jubilant Pharmova Ltd counter

Firstsource Solutions Ltd, Adani Energy Solutions Ltd, Sapphire Foods India Ltd, Lloyds Me...

Read more

2024-08-01 00:00:00

News

Volumes soar at Jubilant Pharmova Ltd counter

Alembic Pharmaceuticals Ltd, Doms Industries Ltd, EPL Ltd, Anand Rathi Wealth Ltd are amon...

Read more

2024-09-09 00:00:00

News

Jubilant Pharmova Ltd leads gainers in 'A' group

Morepen Laboratories Ltd, La Opala RG Ltd, AGI Greenpac Ltd and Gujarat Alkalies & Chemica...

Read more

2024-09-09 00:00:00

News

Jubilant Pharmova gains as Washington unit gets VAI classification from USFDA

The United States Food & Drug Administration (USFDA) conducted an audit of the facility fr...

Read more

2024-09-11 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Jubilant Pharmova Ltd

What is the current PE Ratio of Jubilant Pharmova Ltd?

The Current PE Ratio of Jubilant Pharmova Ltd is 62.95 as on 22 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 22 Nov 2024.

What was the PE Ratio of Jubilant Pharmova Ltd last year?

The PE Ratio of Jubilant Pharmova Ltd was 0.0 last year, now the PE ratio is 62.95, showing a year-on-year growth of -%.

What does the PE Ratio of Jubilant Pharmova Ltd indicate about its stock?

The PE Ratio of Jubilant Pharmova Ltd is 62.95. This ratio indicates that investors are willing to pay 62.95 times the earnings per share for each share of Jubilant Pharmova Ltd.

What is the PE Ratio Growth of Jubilant Pharmova Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Jubilant Pharmova Ltd grew by -% whereas, the EPS ratio grew by -78.7.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*